查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471972

色素减退症治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按治疗、疾病适应症、最终用户和地理位置

Hypopigmentation Disorder Treatment Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment, Disease Indication, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

色素减退症治疗市场预计将从 2023 年的 44 亿美元成长到 2031 年的 67 亿美元；预计2023年至2031年复合年增长率为5.41%。

色素沉着不足症的治疗包括皮肤缺乏正常色素沉着的皮肤状况，从而导致较浅或白色的斑块。几种色素沉着不足的治疗方法旨在恢復或平衡肤色。局部皮质类固醇、光疗和脱色是常见的方法。雷射疗法和细胞疗法等新兴技术已被证明有望使患者受影响的区域重新着色。色素减退性疾病的治疗计划是根据妊娠高血压综合征、白斑症或白化病等特定疾病量身定制的。

色素减退症的盛行率不断增加以及皮肤病学研究的进步推动了色素减退症治疗市场的成长。

色素沉着不足疾病的盛行率不断上升，例如白斑症和白化症。例如，根据 2021 年 7 月《安宁疗护年鑑》发布的资料，全球白斑症盛行率在0.1% 至8% 之间，白斑症与一些自体免疫性和非自体免疫疾病有关，人们对白斑症的认识有所提高，并儘早发现白斑症 诊断有助于增加寻求治疗介入的患者群体。此外，人们美容意识的高涨以及这些人美观的皮肤进一步推动了市场的发展，人们寻求治疗色素沉着不足的疾病。

其次，皮肤科研究和技术的进步导致了创新疗法的发展，包括光疗、局部疗法和外科手术，提高了可用解决方案的功效和范围。此外，与色素减退症治疗市场规模相关的有利报销政策和扩大治疗策略有助于市场成长。製药公司和研究机构之间的合作和伙伴关係加速了新疗法的开发。此外，全球人口老化和皮肤相关疾病的增加增加了对色素沉着不足疾病治疗的需求。总体而言，色素减退症治疗市场是动态的，并且对不断变化的患者需求、技术创新和医疗保健行业内的协作努力做出反应。

色素减退症治疗市场分析是透过考虑以下部分进行的：基于治疗、疾病适应症和最终用户。依治疗方法，市场分为基本外用药物、雷射疗法、化学换肤、微晶磨皮、光疗等。根据疾病适应症，市场分为白糠疹、白斑症、白化症和发炎后色素沉着不足。就最终用户而言，市场分为美容诊所、皮肤科中心和医院。色素减退症治疗市场报告的地理范围包括北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、澳洲） 、韩国和亚太地区其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷以及中南部和中部其他地区）美国）。

就收入而言，由于美国色素减退症患者的盛行率较高，北美在色素减退症治疗市场份额中占据主导地位。此外，对色素沉着不足治疗药物的需求、白斑等色素沉着疾病盛行率的增加以及对色素沉着不足疾病相关意识的提高等因素进一步推动了市场的成长。由于关键产品的推出、製造商或市场参与者的高度集中以及知名竞争对手之间的联盟和收购等多种因素，美国色素减退症治疗市场正在不断增长。此外，关键参与者的策略存在使美国成为色素沉着不足疾病治疗市场成长的关键国家。例如，根据《美国皮肤病学会杂誌》2020 年 12 月的数据，白斑全球盛行率约为 0.5%-2%，报告的发生率因地理位置而异。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：色素沉着减退症治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：色素沉着减退症治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：色素沉着不足疾病治疗市场 - 全球市场分析

  • 色素沉着减退症治疗 - 全球市场概览
  • 色素沉着减退症治疗 - 全球市场和 2031 年预测

第 7 章：色素沉着减退症治疗市场 - 收入分析 - 依治疗方法，2021-2031 年

  • 概述
  • 外用药物
  • 雷射治疗
  • 化学换肤术
  • 微晶磨皮术
  • 光疗
  • 植皮
  • 色素细胞移植
  • 其他的

第 8 章：色素沉着不足疾病治疗市场 - 收入分析 - 按疾病适应症，2021-2031

  • 概述
  • 白斑
  • 白化病
  • 色素减退/色素脱失疤痕
  • 黄褐斑
  • 发炎后色素减退 (PIH)
  • 其他的

第 9 章：色素沉着不足疾病治疗市场 - 收入分析 - 按最终用户，2021-2031 年

  • 概述
  • 医院
  • 美容诊所
  • 皮肤科中心
  • 其他的

第 10 章：色素沉着不足疾病治疗市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 13 章：色素沉着减退症治疗市场 - 主要公司简介

  • Allergan
  • SkinCeuticals
  • Pierre Fabre
  • Episciences, Inc
  • RXi Pharmaceuticals Corporation
  • Obagi Cosmeceuticals LLC
  • Incyte
  • L'oreal Paris
  • CLINUVEL PHARMACEUTICALS LTD
  • STRATA Skin Sciences
  • TeVido BioDevices, Inc.
  • Courage + Khazaka electronic GmbH
  • AVITA Medical
  • Galderma S.A.
  • Vital Esthetique

第 14 章：附录

简介目录
Product Code: TIPRE00004312

The hypopigmentation disorder treatment market is expected to grow from US$ 4.4 billion in 2023 to US$ 6.7 billion by 2031; it is anticipated to record a CAGR of 5.41% from 2023 to 2031.

Hypopigmentation disorder treatment includes skin conditions where the skin lacks normal pigmentation, which results in lighter or white patches. Several therapeutics of hypopigmentation aim to restore or balance skin color. topical corticosteroids, Phototherapy, and depigmentation are common approaches. Emerging technologies, such as laser therapy and cell-based treatments, are shown to promise in repigmenting affected areas of patients. Treatment plans for hypopigmentary disorders are tailored based on specific disorders such as PIH, vitiligo or albinism.

Increasing prevalence of hypopigmentary disorders and advancements in dermatological research drive the growth of the Hypopigmentation Disorder Treatment market.

The rising prevalence of hypopigmentation disorders, such as vitiligo and albinism. For instance, according to the data published in Annals of Palliative Medicine in July 2021, prevalence of vitiligo was reported to range from 0.1% to 8% globally, and vitiligo has been linked to some autoimmune and non-autoimmune diseases and increased awareness and early diagnosis contribute to the increasing patient pool seeking therapeutic interventions. Additionally, a surge in cosmetic consciousness people and the aesthetically pleasing skin among those people further propel the market, with individuals seeking treatments to address hypopigmentation- disorders.

Secondly, advancements in dermatological research and technology resulted in the development of innovative treatments, including phototherapy, topical therapies, and surgical procedures, enhancing the efficacy and scope of available solutions. Moreover, favorable reimbursement policies and expanding treatment strategy related to hypopigmentation disorder treatment market size contribute to market growth. Collaboration and partnerships among pharmaceutical companies and research institutions accelerate the development of novel therapies. Furthermore, the global aging population and the associated increase in skin-related disorders amplify the demand for hypopigmentation disorder treatments. Overall, the hypopigmentation disorder treatment market is dynamic and responsive to evolving patient needs, technological innovations, and collaborative efforts within the healthcare industry.

The hypopigmentation disorder treatment market analysis has been carried out by considering the following segments: based on treatment, disease indication, and end user. By treatment, the market is classified into basic topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others. Based on disease indication, the market is segmented into pityriasis alba, vitiligo, albinism, and post-inflammatory hypopigmentation. In terms of end user, the market is classified into aesthetics clinics, dermatology centers and hospitals. The geographic scope of the hypopigmentation disorder treatment market report includes North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue North America dominated the hypopigmentation disorder treatment market share owing to a higher prevalence of patients suffering from hypo pigmentary disorders in the US. Furthermore, factors like demand for hypopigmentation therapeutics, increasing prevalence of pigmentation disorder such as vitiligo and rising awareness related to hypopigmentation disorders is further driving the market growth. The US hypopigmentation disorder treatment market is growing owing to various factors such as key product introductions, a high concentration of manufacturers or market players, and alliances and acquisitions among prominent competitors. Furthermore, the strategic presence of key players positions US is a key country for the Hypopigmentation Disorder Treatment Market growth. For instance, according to the Journal of American Academy of Dermatology in December 2020, Vitiligo global prevalence is ~0.5%-2%, with reported rates varying geographically .

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hypopigmentation Disorder Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Hypopigmentation Disorder Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Hypopigmentation Disorder Treatment Market - Global Market Analysis

  • 6.1 Hypopigmentation Disorder Treatment - Global Market Overview
  • 6.2 Hypopigmentation Disorder Treatment - Global Market and Forecast to 2031

7. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Treatment, 2021-2031

  • 7.1 Overview
  • 7.2 Topical Drugs
  • 7.3 Laser Therapy
  • 7.4 Chemical Peels
  • 7.5 Microdermabrasion
  • 7.6 Phototherapy
  • 7.7 Skin Grafting
  • 7.8 Pigment cell transplantation
  • 7.9 Others

8. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Vitiligo
  • 8.3 Albinism
  • 8.4 Hypopigmented/depigmented scars
  • 8.5 Melasma
  • 8.6 Post-Inflammatory Hypopigmentation (PIH)
  • 8.7 Others

9. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 9.1 Overview
  • 9.2 Hospitals
  • 9.3 Aesthetic Clinics
  • 9.4 Dermatology Centers
  • 9.5 Others

10. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Hypopigmentation Disorder Treatment Market Overview
    • 10.1.2 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts to 2031
    • 10.1.3 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Treatment
    • 10.1.4 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
    • 10.1.5 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Hypopigmentation Disorder Treatment Market
        • 10.1.6.1.1 United States Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.1.2 United States Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.1.3 United States Hypopigmentation Disorder Treatment Market, by End User
      • 10.1.6.2 Canada Hypopigmentation Disorder Treatment Market
        • 10.1.6.2.1 Canada Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.2.2 Canada Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.2.3 Canada Hypopigmentation Disorder Treatment Market, by End User
      • 10.1.6.3 Mexico Hypopigmentation Disorder Treatment Market
        • 10.1.6.3.1 Mexico Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.3.2 Mexico Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.3.3 Mexico Hypopigmentation Disorder Treatment Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Hypopigmentation Disorder Treatment Market - Key Company Profiles

  • 13.1 Allergan
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 SkinCeuticals
  • 13.3 Pierre Fabre
  • 13.4 Episciences, Inc
  • 13.5 RXi Pharmaceuticals Corporation
  • 13.6 Obagi Cosmeceuticals LLC
  • 13.7 Incyte
  • 13.8 L'oreal Paris
  • 13.9 CLINUVEL PHARMACEUTICALS LTD
  • 13.10 STRATA Skin Sciences
  • 13.11 TeVido BioDevices, Inc.
  • 13.12 Courage + Khazaka electronic GmbH
  • 13.13 AVITA Medical
  • 13.14 Galderma S.A.
  • 13.15 Vital Esthetique

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud